Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

An executive at Tarsus Pharmaceuticals sold 12,274 shares for a transaction value of approximately $839,000, based on a weighted average price of $68.36 per share across three days ending March 19, 2026. The transaction involved only direct ownership; no indirect entities or derivative securities were reported.

IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03 (lotilaner ophthalmic solution) 0.25%, marketed as XDEMVY® in the U.S., by the National Medical Products Administration (NMPA) of the People's Republic of China.

Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

This eye drops stock is building a cup base following the biopharmaceuticals earnings report. Wall Street sees profit on its horizon.

IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

Tarsus Pharmaceuticals remains a Strong Buy, driven by Xdemvy's robust growth and management's $2B+ peak sales target. FY 2025 revenue surged 150% to $451M, with 2026 guidance at $670–$700M and 93% gross margins, though profitability is now expected in 2027. Xdemvy's US market penetration is just 5.6%, with international launches in China (2026) and Europe (2027) set to drive further growth.

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript